SCHEMBL955283

SCHEMBL955283

COc1cccc(F)c1-c1nc(-c2c(C)nn3ccccc23)sc1C(N)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.36
DBF4 Q9UBU7 2/20 0.36
HTR5A P47898 1/20 0.35
PLK1 P53350 3/20 0.35
NEK2 P51955 1/20 0.35
TP53 P04637 1/20 0.34
CTSA P10619 3/20 0.34
F2RL3 Q96RI0 1/20 0.34
MAP4K1 Q92918 1/20 0.34
HTT P42858 1/20 0.33
ATM Q13315 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953764 0.93 PLK1 (0.37) CDC7DBF4PLK1NEK2HTT
SCHEMBL953922 0.92 MAP4K1 (0.36) CTSAF2RL3MAP4K1IRAK4RORC
SCHEMBL955010 0.92 CDC7 (0.40) CDC7DBF4PLK1TP53F2RL3
SCHEMBL951855 0.91 TSHR (0.36) TP53CTSAF2RL3MAP4K1IRAK4
SCHEMBL955503 0.90 CDC7 (0.36) CDC7DBF4PLK1ALDH1A1GAA
SCHEMBL952868 0.90 CDC7 (0.36) CDC7DBF4PLK1NEK2CTSA
SCHEMBL953959 0.89 KMT2A (0.39) CDC7DBF4PLK1NEK2CTSA
SCHEMBL951314 0.87 CDC7 (0.37) CDC7DBF4TP53HTTALDH1A1
SCHEMBL954019 0.87 HTT (0.39) CDC7DBF4PLK1NEK2HTT
SCHEMBL956417 0.85 CDC7 (0.51) CDC7DBF4PLK1TP53CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885HTR5A 3302/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885HTR5A 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.